General Information of Drug (ID: DMP3EXG)

Drug Name
SDZ-205-557 Drug Info
Synonyms 137196-67-9
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5191
ChEBI ID
CHEBI:92288
CAS Number
CAS 137196-67-9
TTD Drug ID
DMP3EXG

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting 5-HT 4 receptor (HTR4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisapride DMY7PED Gastroesophageal reflux disease DA22.Z Approved [2]
Tegaserod DM3XYD1 Irritable bowel syndrome DD91.0 Approved [3]
R0-93877 DMM4U9G Constipation DD91.1 Approved [4]
HTF 919 DM78G6F Constipation DD91.1 Approved [5]
Mosapride DM2VOQ3 N. A. N. A. Phase 4 [6]
Renzapride DM7HQNX Irritable bowel syndrome DD91.0 Phase 3 [7]
Lintopride DMSHGWN Nausea MD90 Phase 2 [8]
TD-8954 DM3C9NV Gastrointestinal disease DE2Z Phase 2 [9]
SB-207266A DM27KFY Irritable bowel syndrome DD91.0 Phase 2 [4]
YKP-GI DM740LV Constipation DD91.1 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 4 receptor (HTR4) TT07C3Y 5HT4R_HUMAN Modulator [1]

References

1 SDZ 205-557, a selective antagonist at 5-HT4 receptors in the isolated guinea pig ileum. Eur J Pharmacol. 1991 Aug 6;200(2-3):373-4.
2 Metoclopramide stimulates catecholamine- and granin-derived peptide secretion from pheochromocytoma cells through activation of serotonin type 4 (5... Endocr Relat Cancer. 2009 Mar;16(1):281-90.
3 Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
4 Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
5 5-Hydroxytryptamine mediated contractions in isolated preparations of equine ileum and pelvic flexure: pharmacological characterization of a new 5-HT(4) agonist. J Vet Pharmacol Ther. 2002 Feb;25(1):49-58.
6 The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jul;378(1):125-37.
7 Pharmacology and metabolism of renzapride : a novel therapeutic agent for the potential treatment of irritable bowel syndrome. Drugs R D. 2008;9(1):37-63.
8 The effects of lintopride, a 5HT-4 antagonist, on oesophageal motility. Aliment Pharmacol Ther. 1995 Oct;9(5):563-9.
9 The Pharmacology of TD-8954, a Potent and Selective 5-HT(4) Receptor Agonist with Gastrointestinal Prokinetic Properties. Front Pharmacol. 2011 May 30;2:25.
10 A randomized trial of 5-hydroxytryptamine4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation. Clin Gastroenterol Hepatol. 2015 Apr;13(4):701-8.e1.